Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease (STEADY-PD)

• ClinicalTrials.gov Identifier: NCT00909545
• Recruitment Status: Completed
• First Posted: May 28, 2009
• Results First Posted: April 17, 2013
• Last Update Posted: April 17, 2013
• Sponsor: Northwestern University
• Collaborators: Michael J. Fox Foundation for Parkinson's Research; Northwestern University Dixon Fund; The Parkinson Study Group
• Information provided by (Responsible Party): Tanya Simuni, Northwestern University

Study Description

Brief Summary:

The primary purpose of this study is to establish a dosage of isradipine CR that is tolerable and demonstrates preliminary efficacy for utilization in future pivotal efficacy studies.

Condition or disease	Intervention/treatment	Phase
Parkinson Disease	Drug: Isradipine CR 5mg; Drug: Isradipine CR 10mg; Drug: Isradipine CR 20mg; Drug: Placebo	Phase 2

Detailed Description:

There is solid scientific rational and preclinical data supporting a clinical trial of isradipine CR as a potential disease modifying agent in early PD. Human pharmacokinetic data demonstrate that it is feasible to achieve the serum concentrations in humans that were neuroprotective in preclinical models with the FDA approved dosage range. Pilot data demonstrate acceptable tolerability of isradipine CR in the PD population. Tolerability is inversely proportional to the dosage dependent. Considering that tolerability of isradipine CR is inversely proportional to the dosage exposure, it is essential to proceed with the dose selection tolerability study in preparation for the future efficacy trials.

The tolerability, defined as the ability to complete the study, of three dosages of isradipine CR relative to placebo in subjects with early Parkinson's disease will be examined first. The dosage that is tolerable and demonstrates preliminary efficacy will be evaluated further in the future pivotal efficacy studies.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 99 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
• Study Start Date: July 2009
• Actual Primary Completion Date: December 2011
• Actual Study Completion Date: February 2012

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Isradipine CR 5mg; Isradipine CR 5mg/day	Drug: Isradipine CR 5mg; 5mg dose: 1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily; Other Names: Isradipine CR; Dynacirc CR
Active Comparator: Isradipine CR 10mg; Isradipine CR 10mg/day	Drug: Isradipine CR 10mg; 10mg dose: 2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily; Other Names: Isradipine CR; Dynacirc CR
Active Comparator: Isradipine CR 20mg; Isradipine CR 20mg/day	Drug: Isradipine CR 20mg; 20mg dose: 4 Dynacirc CR 5mg tablets once daily; Other Names: Isradipine CR; Dynacirc CR
Placebo Comparator: Placebo; Placebo	Drug: Placebo; 4 Placebo to Match (PTM) tablets once daily

Outcome Measures

Primary Outcome Measures :

1. Tolerability of the Three Dosages(5mg, 10mg and 20mg) of Isradipine CR. [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
   Tolerability will be judged by the proportion of subjects enrolled in a dosage group able to complete the 12 month study or to the time of initiation of dopaminergic therapy on their original assigned dosage. Tolerability of each active arm will be compared to placebo group.

Secondary Outcome Measures :

1. Efficacy: Change in Unified Parkinson's Disease Rating Scale (UPDRS) [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
   Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 12 or the time to require dopaminergic therapy (last visit before subject goes on dopaminergic therapy), whichever occurs first. The UPDRS score has 4 components. Part I assesses mentation; Part II assesses activities of daily living; Part III assesses motor abilities; Part IV assesses complications of therapy. A total of 44 items are included in Parts I-III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Part IV contains 11 items, 4 of these items are scored 0-4 in the same manner, and 7 are scored 0-1, with 0 indicating the absence of impairment and 1 indicating the presence of impairment. Total UPDRS score represents the sum of these items in Parts I-IV. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability.
2. Efficacy: Change in Mental Subscales of the Unified Parkinson's Disease Rating Scale [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
   The outcome is defined as change in Mental subscale of Unified Parkinson's Disease Rating Scale(UPDRS Part I) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part I: Mentation, behavior and mood, consisting of 4 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score represents the sum of these 4 questions. A greater increase in score indicates a greater increase in disability. A total of 16 points are possible. 16 represents the worst (total) disability), 0--no disability.
3. Efficacy: Change in Activities of Daily Living(ADL) Subscale of the Unified Parkinson's Disease Rating Scale [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
   The outcome is defined as change in ADL subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part II) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part II: Activities of Daily Living in the week prior to the designated visit, consisting of 13 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part II score represents the sum of these 13 questions. A greater increase in score indicates a greater increase in disability. A total of 52 points are possible. 52 represents the worst (total) disability), 0--no disability
4. Efficacy: Change in Motor Subscale of the Unified Parkinson's Disease Rating Scale [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
   The outcome is defined as change in Motor subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part III) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part III: motor abilities at the time of the visit, consisting of 27 items (including 13 general questions and 14 sub-questions) each answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part III score represents the sum of these 27 items. A total of 108 points are possible. 108 represents the worst (total) disability), 0--no disability.
5. Efficacy: Change in Modified Hoehn & Yahr Scale [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
   The Modified Hoehn & Yahr Scale is an 8-level Parkinson's disease staging instrument. The outcome is defined as change in Modified Hoehn & Yahr Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. A greater increase in stage indicates a greater increase in disability. Stage ranges from 0-5 (also including 1.5 and 2.5) with 0 indicating no disability and 5 indicating maximum disability.
6. Efficacy: Change in Modified Schwab & England Independence Scale [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
   The Schwab & England scale is an investigator and subject assessment of the subject's level of independence at all scheduled study visits. The subject will be scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to what he/she did before Parkinson's disease appeared. The outcome is defined as change in Schwab & England Independence Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Higher decrease in score indicates higher disability. Score ranges from 100% (complete independence) to 0% (total disability).
7. Efficacy: Change in Beck Depression Inventory II (BDI-II) [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
   The Beck Depression Inventory (BDI) is a validated self-reported 21-item depression scale that was tested and validated as a reliable instrument for screening for depression in PD. The outcome is defined as change in BDI-II between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total BDI score represents the sum of these 21-items. A higher change in score indicates a greater increase in disability. Total score of 0-13 is considered minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.
8. Efficacy: Change in Montreal Cognitive Assessment [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
   The Montreal Cognitive Assessment(MoCA) is a brief 30-point screening instrument that was developed and validated to identify subjects with mild cognitive impairment. The outcome is defined as change in MoCA between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total MoCA score represents the sum of these 30-points, with a lower score indicating greater cognitive impairment. 30 is the maximum score, with a score of 26 or higher considered normal and below 26 indicative of Mild Cognitive Impairment.
9. Efficacy: Change in Parkinson Disease Quality of Life Questionnaire-39(PDQ-39) [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
   The PD Quality of Life Scale(PDQ-39) asks the subject to evaluate how Parkinson disease has affected their health and overall quality of life at that point in time. The total quality of life scale includes subscales relating to social role, self-image/sexuality, sleep, outlook, physical function and urinary function. The outcome is defined as change in PDQ-39 between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. It is scored on a scale of zero to 100, with lower scores indicating better health and higher scores more severe disability.
10. Vital Signs: Change in Systolic Standing [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
11. Vital Signs: Change in Systolic Supine [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
12. Vital Signs: Change in Diastolic Standing [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
13. Vital Signs: Change in Diastolic Supine [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
14. Vital Signs: Change in Pulse Standing [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
15. Vital Signs: Change in Pulse Supine [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
16. Common Adverse Events: Oedema Peripheral [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
    General disorders and administration site conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects.
17. Common Adverse Events: Dizziness [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
    Nervous system disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.
18. Common Adverse Events: Nasopharyngitis [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
    Infections and infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.
19. Common Adverse Events: Headache [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
    Nervous System disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.
20. Common Adverse Events: Constipation [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
    Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.
21. Common Adverse Events: Fatigue [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
    General Disorders and Administration Site Conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.
22. Common Adverse Events: Nausea [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
    Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.
23. Common Adverse Events: Upper Respiratory Tract Infection [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
    Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.
24. Common Adverse Events: Depression [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
    Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.
25. Common Adverse Events: Somnolence [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
    Nervous System Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.
26. Common Adverse Events: Insomnia [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
    Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.
27. Common Adverse Events: Dyspepsia [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
    Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.
28. Common Adverse Events: Diarrhoea [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
    Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.
29. Common Adverse Events: Sinusitis [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
    Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.
30. Common Adverse Events: Back Pain [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
    Musculoskeletal and Connective Tissue Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.
31. Common Adverse Events: Hypotension [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ]
    Vascular Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.

Eligibility Criteria

• Ages Eligible for Study: 30 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Subjects with early idiopathic PD. If tremor is not present, subjects must have unilateral onset and persistent asymmetry of the symptoms.
• Be over 30 years old at the time of diagnosis of PD.
• Hoehn & Yahr stage is less than or equal to 2.5.
• Currently not receiving dopaminergic therapy and not projected to require dopaminergic therapy for at least 6 months from enrollment.
• Use of MAO-B inhibitors (rasagiline, selegiline), amantadine, or anticholinergics will be allowed. The dosage has to be stable for 3 months prior to baseline visit and throughout the duration of the study.

Exclusion Criteria:

• Subjects with a diagnosis of an atypical Parkinsonism
• Subjects unwilling or unable to give informed consent
• Use of CoQ10 at a dosage >600mg daily or use of creatine >5 grams daily within the 60 days prior to randomization
• Exposure to dopaminergic PD therapy within 60 days prior to enrollment or for 3 months or more at any point in the past
• History of clinically significant orthostatic hypotension or presence of orthostatic hypotension at the screening visit defined as > 20 mmHg change in systolic BP and >10mm change in diastolic BP after 2 min of standing, or baseline BP <90/60
• History of congestive heart failure
• History of bradycardia defined as heart rate <55
• Presence of 2nd or 3rd degree atrioventricular block or other significant ECG abnormalities that in the investigator's opinion would compromise participation in study
• Clinically significant abnormalities in the Screening Visit laboratory studies or electrocardiogram.
• Presence of other known medical or psychiatric comorbidity that in the investigator's opinion would compromise participation in the study
• Prior exposure to isradipine or other calcium channel blockers within 6 months of baseline
• Subjects with history of hypertension treated with a maximum of 2 other antihypertensive agents will be allowed provided that the doses of concomitant anti HTN therapy can be reduced/adjusted during the study based on the BP readings in consultation with the subject's primary care physician or cardiologist.
• Use of grapefruit juice, Ginkgo biloba, St. John's wart and/or ginseng will be prohibited during the study (as they interfere with the metabolism of isradipine).
• Presence of cognitive dysfunction defined by a Mini Mental Status Exam ( MMSE) score < 26 at screening
• Subjects with clinically significant depression as determined by a Beck Depression Inventory (BDI) score >15 at screening
• History of exposure to typical or atypical antipsychotics or other dopamine blocking agents within 6 months prior to enrollment
• Subjects have to be on a stable regimen of central nervous system acting medications (benzodiazepines, antidepressants, hypnotics) for 30 days prior to enrollment
• Lactating women or women of childbearing potential who are not surgically sterilized have to use a reliable measure of contraception and have a negative serum pregnancy test at screening
• Participation in other investigational drug trials within 30 days prior to screening
• History of brain surgery for PD

Contacts and Locations

Locations

United States, California

Parkinson Institute

Sunnyvale, California, United States, 94805

United States, Connecticut

Institute for Neurodegenerative Disorders

New Haven, Connecticut, United States, 06510

United States, Florida

Mayo Clinic Jacksonville

Jacksonville, Florida, United States, 32224

University of Miami

Miami, Florida, United States, 33136

University of South Flordia

Tampa, Florida, United States, 33606

United States, Georgia

Emory University School of Medicine

Atlanta, Georgia, United States, 30329

United States, Hawaii

Pacific Health Institute

Honolulu, Hawaii, United States, 96817

United States, Illinois

Northwestern University

Chicago, Illinois, United States, 60611

Rush University Medical Center

Chicago, Illinois, United States, 60612

United States, Massachusetts

Boston University

Boston, Massachusetts, United States, 02118

United States, Michigan

Michigan State University

East Lansing, Michigan, United States, 48824

United States, Minnesota

Park Nicolet Clinic

Golden Valley, Minnesota, United States, 55427

University of Minnesota

Minneapolis, Minnesota, United States, 55455

United States, Missouri

Washington University

St. Louis, Missouri, United States, 63110

United States, New York

University of Rochester

Rochester, New York, United States, 14618

United States, Ohio

University of Cincinnati

Cincinnati, Ohio, United States, 45219

United States, Pennsylvania

University of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15213

United States, Tennessee

University of Tennessee

Memphis, Tennessee, United States, 38104

Canada, Ontario

Ottowa Hospital Civic Site

Ottawa, Ontario, Canada, K1Y 4E9

Toronto Western Hospital

Toronto, Ontario, Canada, M5T 2S8

Sponsors and Collaborators

Northwestern University

Michael J. Fox Foundation for Parkinson's Research

Northwestern University Dixon Fund

The Parkinson Study Group

Investigators

• Study Chair: Tanya Simuni, MS; Northwestern University

More Information

Publications:

Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993 Jan 21;328(3):176-83. doi: 10.1056/NEJM199301213280305.

Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002 Apr 3;287(13):1653-61. doi: 10.1001/jama.287.13.1653.

Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004 Apr;61(4):561-6. doi: 10.1001/archneur.61.4.561.

NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006 Mar 14;66(5):664-71. doi: 10.1212/01.wnl.0000201252.57661.e1. Epub 2006 Feb 15.

NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007 Jan 2;68(1):20-8. doi: 10.1212/01.wnl.0000250355.28474.8e.

Becker C, Jick SS, Meier CR. Use of antihypertensives and the risk of Parkinson disease. Neurology. 2008 Apr 15;70(16 Pt 2):1438-44. doi: 10.1212/01.wnl.0000303818.38960.44. Epub 2008 Feb 6.

Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004 Oct;318(1):121-34. doi: 10.1007/s00441-004-0956-9. Epub 2004 Aug 24.

Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, Meredith GE, Surmeier DJ. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature. 2007 Jun 28;447(7148):1081-6. doi: 10.1038/nature05865. Epub 2007 Jun 10.

Christensen HR, Antonsen K, Simonsen K, Lindekaer A, Bonde J, Angelo HR, Kampmann JP. Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration: half-life shorter than expected? Pharmacol Toxicol. 2000 Apr;86(4):178-82. doi: 10.1034/j.1600-0773.2000.d01-32.x.

de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006 Jun;5(6):525-35. doi: 10.1016/S1474-4422(06)70471-9.

Dodel RC, Singer M, Kohne-Volland R, Szucs T, Rathay B, Scholz E, Oertel WH. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics. 1998 Sep;14(3):299-312. doi: 10.2165/00019053-199814030-00006.

Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007 Jan 30;68(5):384-6. doi: 10.1212/01.wnl.0000247740.47667.03. Epub 2006 Nov 2.

Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch YY, Huang P, Guimaraes P, Kamp C, Tilley BC, Kieburtz K; NET-PD Investigators. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb;57(2):197-203. doi: 10.1002/ana.20361.

Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 Dec 9;351(24):2498-508. doi: 10.1056/NEJMoa033447.

Gill DJ, Freshman A, Blender JA, Ravina B. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. Mov Disord. 2008 May 15;23(7):1043-1046. doi: 10.1002/mds.22017.

Goetz CG, LeWitt PA, Weidenman M. Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program. Mov Disord. 2003 Dec;18(12):1455-8. doi: 10.1002/mds.10591.

Goetz CG, Stebbins GT, Chmura TA, Fahn S, Klawans HL, Marsden CD. Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord. 1995 May;10(3):263-6. doi: 10.1002/mds.870100305.

Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson's disease. Mov Disord. 2005 Nov;20(11):1449-54. doi: 10.1002/mds.20609.

Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002 Mar;8(4):271-6. doi: 10.1016/s1353-8020(01)00040-2.

Johnson BA, Javors MA, Lam YW, Wells LT, Tiouririne M, Roache JD, Ait-Daoud N, Lawson K. Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jan;29(1):15-20. doi: 10.1016/j.pnpbp.2004.08.014. Epub 2004 Nov 11.

Kupsch A, Sautter J, Schwarz J, Riederer P, Gerlach M, Oertel WH. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res. 1996 Nov 25;741(1-2):185-96. doi: 10.1016/s0006-8993(96)00917-1.

Leentjens AF, Verhey FR, Luijckx GJ, Troost J. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov Disord. 2000 Nov;15(6):1221-4. doi: 10.1002/1531-8257(200011)15:63.0.co;2-h.

Levy G, Kaufmann P, Buchsbaum R, Montes J, Barsdorf A, Arbing R, Battista V, Zhou X, Mitsumoto H, Levin B, Thompson JL. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology. 2006 Mar 14;66(5):660-3. doi: 10.1212/01.wnl.0000201182.60750.66.

Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x. Erratum In: J Am Geriatr Soc. 2019 Sep;67(9):1991.

Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001 Jun;56(11 Suppl 5):S1-S88. doi: 10.1212/wnl.56.suppl_5.s1. No abstract available.

Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res. 1995 Jun;4(3):241-8. doi: 10.1007/BF02260863.

Richards M, Marder K, Cote L, Mayeux R. Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination. Mov Disord. 1994 Jan;9(1):89-91. doi: 10.1002/mds.870090114.

Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002 Oct;59(10):1541-50. doi: 10.1001/archneur.59.10.1541.

Simuni T, Borushko E, Avram MJ, Miskevics S, Martel A, Zadikoff C, Videnovic A, Weaver FM, Williams K, Surmeier DJ. Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. Mov Disord. 2010 Dec 15;25(16):2863-6. doi: 10.1002/mds.23308.

Striessnig J, Koschak A, Sinnegger-Brauns MJ, Hetzenauer A, Nguyen NK, Busquet P, Pelster G, Singewald N. Role of voltage-gated L-type Ca2+ channel isoforms for brain function. Biochem Soc Trans. 2006 Nov;34(Pt 5):903-9. doi: 10.1042/BST0340903.

Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr 11;66(7):976-82. doi: 10.1212/01.wnl.0000206363.57955.1b. Erratum In: Neurology. 2006 Jul 25;67(2):299.

Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord. 2003 Jan;18(1):19-31. doi: 10.1002/mds.10305.

Urien S, Pinquier JL, Paquette B, Chaumet-Riffaud P, Kiechel JR, Tillement JP. Effect of the binding of isradipine and darodipine to different plasma proteins on their transfer through the rat blood-brain barrier. Drug binding to lipoproteins does not limit the transfer of drug. J Pharmacol Exp Ther. 1987 Jul;242(1):349-53.

Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ; REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003 Jul;54(1):93-101. doi: 10.1002/ana.10609.

Zadikoff C, Fox SH, Tang-Wai DF, Thomsen T, de Bie RM, Wadia P, Miyasaki J, Duff-Canning S, Lang AE, Marras C. A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord. 2008 Jan 30;23(2):297-9. doi: 10.1002/mds.21837.

• Responsible Party: Tanya Simuni, Prinicpal Investigator, Northwestern University
• ClinicalTrials.gov Identifier: NCT00909545
• Other Study ID Numbers: CTCC Protocol #124
• First Posted: May 28, 2009
• Results First Posted: April 17, 2013
• Last Update Posted: April 17, 2013
• Last Verified: April 2013

Keywords provided by Tanya Simuni, Northwestern University:

Early Parkinson disease

Additional relevant MeSH terms:

Parkinson Disease; Isradipine; Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Antihypertensive Agents; Calcium Channel Blockers; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action; Calcium-Regulating Hormones and Agents; Physiological Effects of Drugs; Vasodilator Agents